ImmuPharma celebrates "significant milestone" for P140 platform

(Alliance News) - ImmuPharma PLC on Thursday announced "new discoveries" regarding the mechanism of action of its P140 autoimmune technology platform.

As a result, shares in ImmuPharma were up 1.6% at 3.41 pence late on Thursday afternoon in London.

These discoveries, the London-based specialist drug discovery and development company said, provide for the first time direct evidence of a major key hypothesis of the unique MOA of P140.

ImmuPharma also said that P140 has been found not to block or reduce the body's ability to mount a specific immune response, unlike "the most advanced therapies currently available" to treat autoimmune diseases.

Finally, the findings "confirm P140's potential as a safe and effective treatment for patients suffering from systemic lupus erythematosus", the firm said.

ImmuPharma said the findings are from a new preclinical study designed by ImmuPharma Biotech's team, and will allow the company "to further expand its intellectual property portfolio, with additional new patents, strengthening [P140's] commercial viability".

The company said that detailed data from the study will be released in due course.

Chief Executive Officer Tim McCarthy commented: "These stunning results clearly demonstrate the unique MOA of P140 and this data adds significantly to our ongoing discussions with potential partners and our objective to secure the optimum deal[s] for our shareholders."

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Immupharma